<<VOLVER
Miguel Martin
Hospital General Universitario Gregorio Marañón, Madrid, Spain
Introduction
Kornelia Polyak
Dana-Farber Cancer Institute, Boston, USA
Tumor heterogeneity in breast cancer
download slides
Nicholas Navin
The University of Texas MD Anderson Cancer Center, Houston, USA
Quantifying tumor heterogeneity in breast cancer
download slides
Jeffrey Pollard
MRC Centre for Reproductive Health, University of Edinburgh, UK
The microenvironment in breast cancer: biology and clinical implications
download slides
Lajos Pusztai
Yale University Cancer Center, New Haven, USA
Next-generation sequencing assay in primary and metastatic breast cancers: implications for clinical practice
download slides
Fabrice André
Gustave Roussy Cancer Campus, Villejuif, France
Screening breast cancer for drugable targets: the French UNICANCER experience
download slides
Andrew Tutt
King's College London and Institute of Cancer Research, London, UK
DNA repair deficiencies and PARP inhibitors in triple negative breast cancer
download slides
Michael Untch
HELIOS Klinikum Berlin-Buch, Berlin, Germany
Ongoing and recent neoadjuvant trials in HER2-negative patients
download slides

Joan Albanell
Hospital del Mar, Barcelona, Spain
Metastatic triple negative breast cancer: ongoing trials
download slides
Francisco Esteva
NYU Langone Medical Center, New York, USA
Mechanism of resistance to anti-HER2 agents
download slides
Nadia Harbeck
Breast Center, University of Munich (LMU), Munich, Germany
Neoadjuvant therapy of HER2 positive breast cancer:
current standards and potential role of non-chemotherapy regimens
download slides

Sunil Verma
Sunnybrook Odette Cancer Centre, University of Toronto, Canada
Advances in the management of metastatic HER-2 positive breast cancer
download slides
<<VOLVER